Neogenomics, Inc.
NEO
$7.88
-$0.10-1.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -9.88M | -27.13M | -45.09M | -25.92M | -15.32M |
| Total Depreciation and Amortization | 16.40M | 16.44M | 17.26M | 17.73M | 18.19M |
| Total Amortization of Deferred Charges | 383.00K | 381.00K | 498.00K | 735.00K | 732.00K |
| Total Other Non-Cash Items | 10.09M | 19.42M | 33.65M | 12.38M | 10.27M |
| Change in Net Operating Assets | -15.64M | -226.00K | 14.01M | -30.24M | -4.07M |
| Cash from Operations | 1.34M | 8.88M | 20.33M | -25.33M | 9.80M |
| Capital Expenditure | -7.87M | -8.31M | -6.32M | -4.50M | -11.60M |
| Sale of Property, Plant, and Equipment | 2.07M | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | -463.00K | -5.99M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -500.00K | 8.50M | 3.00M | 8.06M | 6.13M |
| Cash from Investing | -6.31M | -277.00K | -9.31M | 3.56M | -5.47M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | 0.00 | -201.25M | -- | -- |
| Issuance of Common Stock | 431.00K | 531.00K | -- | 949.00K | 3.54M |
| Repurchase of Common Stock | -- | -- | -949.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 234.00K | -234.00K | -- | -2.86M |
| Cash from Financing | 431.00K | 765.00K | -202.43M | 949.00K | 687.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | 32.00K | 22.00K | -54.00K | -- | -- |
| Net Change in Cash | -4.50M | 9.39M | -191.47M | -20.82M | 5.02M |